Aura Biosciences Inc

For the period ended Mar 31, 2025. Filed May 15, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2025 · Filed May 15, 2025

AURA$7.65-0.1%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Stockholders’ Equity

(in thousands, except share data)

Additional · Accumulated · Total
Common Stock · Paid-In · Accumulated · Other Comprehensive · Stockholders’
	Shares	Amount	Capital	Deficit	Income	Equity
Balance, December 31, 2024	49,998,279	$—	$525,934	$(374,227)	$263	$151,970
Stock-based compensation expense	—	—	3,514	—	—	3,514
Employee Stock Purchase Plan issuance	15,263	—	96	—	—	96
Vesting of restricted stock	211,770	—	—	—	—	—
Unrealized loss on marketable securities	—	—	—	—	(137)	(137)
Currency translation adjustment	—	—	—	—	(21)	(21)
Other	—	—	27	—	—	27
Net loss	—	—	—	(27,483)	—	(27,483)
Balance, March 31, 2025	50,225,312	$—	$529,571	$(401,710)	$105	$127,966
Additional · Accumulated · Total
Common Stock · Paid-In · Accumulated · Other Comprehensive · Stockholders’
	Shares	Amount	Capital	Deficit	Income	Equity
Balance, December 31, 2023	49,350,788	$—	$512,617	$(287,308)	$539	$225,848
Stock-based compensation expense	—	—	2,909	—	—	2,909
Employee Stock Purchase Plan issuance	12,314	—	95	—	—	95
Stock option exercises	51,180	—	158	—	—	158
Vesting of restricted stock	90,123	—	—	—	—	—
Unrealized loss on marketable securities	—	—	—	—	(521)	(521)
Net loss	—	—	—	(19,706)	—	(19,706)
Balance, March 31, 2024	49,504,405	$—	$515,779	$(307,014)	$18	$208,783

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.